by Russell McAllister 05-28-2020

Bold Therapeutics and Hana Pharm Execute Option Agreement for Exclusive Development and Commercialization Rights to BOLD-100 in South Korea

Bold Therapeutics announced it has executed an option agreement with Hana Pharm Co. for BOLD-100 in South Korea.

Russell McAllister 04-15-2020

Bold Therapeutics and the University of Ottawa Initiate Research Partnership to Study BOLD-100 in the Treatment of COVID-19

Bold Therapeutics announced a research partnership with the University of Ottawato to explore the potential utility of BOLD-100 as a novel antiviral agent.

Russell McAllister 03-27-2020

Bold Therapeutics Seeks Collaborators for Rapid Development of BOLD-100; Lead Drug Candidate Has Potential Utility in the Treatment of COVID-19

Bold Therapeutics announced that recent developments have suggested the potential utility of its lead drug BOLD-100 as a novel antiviral agent.

Russell McAllister 03-27-2020

Bold Therapeutics to Initiate Phase 1b Trial of BOLD-100 in GI Cancers

Bold Therapeutics announced that it has received clearance from Health Canada to initiate a Phase 1b trial.

Mark Bazett 02-10-2020

Bold Therapeutics Visiting Collaborators in Europe

Bold Therapeutics will be visiting with multiple collaborators, vendors and partners in Europe from March 2nd to 6th.

View All